why choose us

First received: March 03, 2025

Clinical Trial: Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Anthracyclines-Induced Cardiotoxicity

Study Type: INTERVENTIONAL


Official Title: Mitigating Anthracycline-Induced Cardiac Toxicity With Dapagliflozin: A Randomized, Double-Blind, Placebo-Controlled Trial of 10 mg Daily for Four Months

Brief Summary: Brief Summary Anthracyclines (e.g., doxorubicin) are effective anticancer agents but can cause dose-dependent, often irreversible cardiotoxicity via oxidative stress, mitochondrial dysfunction, and cardiomyocyte apoptosis.Trastuzumab is also associated with left-ventricular dysfunction, typically reversible.The original protocol planned cohorts for both drug classes; however, no trastuzumab patients were enrolled due to feasibility, and the final study focused exclusively on anthracycline-treated…

Read more